The World Health Organisation (WHO) has prequalified the first diagnostic test for glucose-6-phosphate dehydrogenase (G6PD) deficiency, a critical tool for safely administering WHO-recommended treatments to prevent relapse of Plasmodium vivax (P. vivax) malaria.
Trending
- Butchers seek FG’s intervention as cow price skyrockets to N2m
- NAFDAC denies report indicting PCN over counterfeit drug distribution
- Dangote Group paid N402.3bn in taxes to Nigerian govt in 2024
- IWD: NACA reaffirms commitment to women’s healthcare
- Jigawa, UNICEF sensitise women on environmental sustainability
- Parents express concern over suspected Diphtheria outbreak in King’s College, Lagos
- Pharmacist calls for funding of research on herbal medicine in Nigeria
- FULL LIST: Facilities for free Comprehensive Emergency Obstetric Care, VVF surgeries
